[1] CHEN W, XU Z M, WANG G, et al. Non-motor symptoms of Parkinson's disease in China:a review of the literature[J]. Parkinsonism Relat Disord, 2012, 18(5):446-452.
[2] LIN L, DU Y Q, YUAN S T, et al. Serum melatonin is an alternative index of Parkinson's disease severity[J]. Brain Res, 2014, 1547:43-48.
[3] KUNZ D, BES F. Twenty years after:another case report of melatonin effects on REM sleep behavior disorder, using serial dopamine transporter imaging[J]. Neuropsychobiology, 2017, 76(2):100-104.
[4] SIMON D K, TANNER C M, BRUNDIN P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology[J]. Clin Geriatr Med, 2020, 36(1):1-12.
[5] LIDDELL J R, WHITE A R. Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease[J]. Neurochem Int, 2018, 117:126-138.
[6] WU Z, GENG Y, BUIST-HOMAN M, et al. Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic Reticulum stress and oxidative stress[J]. Toxicol Appl Pharmacol, 2021:2021Dec31;115858.
[7] SCHAPIRA A H V. Mitochondria in the aetiology and pathogenesis of Parkinson's disease[J]. Lancet Neurol, 2008, 7(1):97-109.
[8] CHEN Q Q, HAIKAL C, LI W, et al. Gut inflammation in association with pathogenesis of Parkinson's disease[J]. Front Mol Neurosci, 2019, 12:218.
[9] KLONGPANICHAPAK S, PHANSUWAN-PUJITO P, EBADI M, et al. Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells[J]. Neurosci Lett, 2008, 436(3):309-313.
[10] HSU L J, SAGARA Y, ARROYO A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress[J]. Am J Pathol, 2000, 157(2):401-410.
[11] SHAMS R, BANIK N L, HAQUE A. Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease[J]. Prog Mol Biol Transl Sci, 2019, 167:107-124.
[12] GHIO S, KAMP F, CAUCHI R, et al. Interaction of α-synuclein with biomembranes in Parkinson's disease:role of cardiolipin[J]. Prog Lipid Res, 2016, 61:73-82.
[13] TAMTAJI O R, REITER R J, ALIPOOR R, et al. Melatonin and parkinson disease:current status and future perspectives for molecular mechanisms[J]. Cell Mol Neurobiol, 2020, 40(1):15-23.
[14] MAZURSKYY A, HOWITT J. Initiation and transmission of α-synuclein pathology in Parkinson's disease[J]. Neurochem Res, 2019, 44(12):2685-2694.
[15] SRINIVASAN V, SPENCE D W, PANDI-PERUMAL S R, et al. Melatonin in mitochondrial dysfunction and related disorders[J]. Int J Alzheimers Dis, 2011, 2011:326320.
[16] SUWANJANG W, PHANSUWAN-PUJITO P, GOVITRAPONG P, et al. The protective effect of melatonin on methamphetamine-induced calpain-dependent death pathway in human neuroblastoma SH-SY5Y cultured cells[J]. J Pineal Res, 2010, 48(2):94-101.
[17] ZAITONE S A, HAMMAD L N, FARAG N E. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine-parkinsonian mice[J]. Pharmacol Rep, 2013, 65(5):1213-1226.
[18] DÍAZ-CASADO M E, RUSANOVA I, ARANDA P, et al. In vivo determination of mitochondrial respiration in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated zebrafish reveals the efficacy of melatonin in restoring mitochondrial normalcy[J]. Zebrafish, 2018, 15(1):15-26.
[19] TOCHARUS J, KHONTHUN C, CHONGTHAMMAKUN S, et al. Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines[J]. J Pineal Res, 2010, 48(4):347-352.
[20] ZHOU H Y, CHEANG T, SU F J, et al. Melatonin inhibits rotenone-induced SH-SY5Y cell death via the downregulation of Dynamin-Related Protein 1 expression[J]. Eur J Pharmacol, 2018, 819:58-67.
[21] DÍAZ-CASADO M E, LIMA E, GARCÍA J A, et al. Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network[J]. J Pineal Res, 2016, 61(1):96-107.
[22] NIRANJAN R, NATH C, SHUKLA R. The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6[J]. Free Radic Res, 2010, 44(11):1304-1316.
[23] ORTIZ G G, PACHECO-MOISÉS F P, GóMEZ-RODRÍGUEZ V M, et al. Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine[J]. Metab Brain Dis, 2013, 28(4):705-709.
[24] SCHLACHETZKI J C M, GRIMM T, SCHLACHETZKI Z, et al. Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α-synuclein[J]. J Neurosci Res, 2016, 94(1):62-73.
[25] CHANG C F, HUANG H J, LEE H C, et al. Melatonin attenuates kainic acid-induced neurotoxicity in mouse Hippocampus via inhibition of autophagy and α-synuclein aggregation[J]. J Pineal Res, 2012, 52(3):312-321.
[26] RADOGNA F, ALBERTINI M C, DE NICOLA M, et al. Melatonin promotes Bax sequestration to mitochondria reducing cell susceptibility to apoptosis via the lipoxygenase metabolite 5-hydroxyeicosatetraenoic acid[J]. Mitochondrion, 2015, 21:113-121.
[27] NOPPARAT C, PORTER J E, EBADI M, et al. The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy[J]. J Pineal Res, 2010, 49(4):382-389.
[28] KONGSUPHOL P, MUKDA S, NOPPARAT C, et al. Melatonin attenuates methamphetamine-induced deactivation of the mammalian target of rapamycin signaling to induce autophagy in SK-N-SH cells[J]. J Pineal Res, 2009, 46(2):199-206.
[29] SU L Y, LI H, LV L, et al. Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation[J]. Autophagy, 2015, 11(10):1745-1759.
[30] KASHIHARA K, NOMURA T, MAEDA T, et al. Beneficial effects of ramelteon on rapid eye movement sleep behavior disorder associated with Parkinson's disease-results of a multicenter open trial[J]. Intern Med, 2016, 55(3):231-236.
[31] GILAT M, JACKSON A C, MARSHALL N S, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease:a randomised controlled trial[J]. Mov Disord, 2020, 35(2):344-349. |
